WO2015104602A3 - A process for the preparation of anagliptin and its intermediates thereof - Google Patents

A process for the preparation of anagliptin and its intermediates thereof Download PDF

Info

Publication number
WO2015104602A3
WO2015104602A3 PCT/IB2014/066915 IB2014066915W WO2015104602A3 WO 2015104602 A3 WO2015104602 A3 WO 2015104602A3 IB 2014066915 W IB2014066915 W IB 2014066915W WO 2015104602 A3 WO2015104602 A3 WO 2015104602A3
Authority
WO
WIPO (PCT)
Prior art keywords
anagliptin
preparation
present
intermediates
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2014/066915
Other languages
French (fr)
Other versions
WO2015104602A2 (en
Inventor
Naveen Reddy
Damodara NAIDU
Pramodkumar SHARMA
Bhatraju Srinivasa RAO
Keshav Deo
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Priority claimed from IN70MU2014 external-priority patent/IN2014MU00070A/en
Priority claimed from IN69MU2014 external-priority patent/IN2014MU00069A/en
Publication of WO2015104602A2 publication Critical patent/WO2015104602A2/en
Publication of WO2015104602A3 publication Critical patent/WO2015104602A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention relates to an improved process for the preparation of Anagliptin, intermediates thereof, or pharmaceutically acceptable thereof. The present invention also direct to another short process for the preparation of Anagliptin. The present invention also specifically provides an improved process for the purification of intermediate of Anagliptin. Further, the present invention relates to a polymorph of Anagliptin or a pharmaceutically acceptable salt thereof and a method for the preparation thereof.
PCT/IB2014/066915 2014-01-08 2014-12-15 A process for the preparation of anagliptin and its intermediates thereof WO2015104602A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN70/MUM/2014 2014-01-08
IN69/MUM/2014 2014-01-08
IN564/MUM/2014 2014-02-18
IN564MU2014 2014-02-18
IN70MU2014 IN2014MU00070A (en) 2014-01-08 2014-12-15
IN69MU2014 IN2014MU00069A (en) 2014-01-08 2014-12-15

Publications (2)

Publication Number Publication Date
WO2015104602A2 WO2015104602A2 (en) 2015-07-16
WO2015104602A3 true WO2015104602A3 (en) 2015-12-10

Family

ID=52462959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/066915 WO2015104602A2 (en) 2014-01-08 2014-12-15 A process for the preparation of anagliptin and its intermediates thereof

Country Status (1)

Country Link
WO (1) WO2015104602A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003218B (en) * 2019-03-26 2020-07-31 杭州瀚康生物医药科技有限公司 Preparation method of Allagliptin intermediate
RU2727898C1 (en) * 2020-02-25 2020-07-24 Общество с ограниченной ответственностью «Необиотек» Pharmaceutical composition based on an active substance, an inhibitor of dipeptidyl peptidase-4, for preventing the development and treatment of type 2 diabetes mellitus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595866A1 (en) * 2003-01-31 2005-11-16 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
WO2006060122A2 (en) * 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
WO2009047240A1 (en) * 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010064982A (en) 2008-09-10 2010-03-25 Dainippon Sumitomo Pharma Co Ltd Alkylamino derivative
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
US20120220603A1 (en) 2009-09-04 2012-08-30 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595866A1 (en) * 2003-01-31 2005-11-16 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
WO2006060122A2 (en) * 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
WO2009047240A1 (en) * 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN SCHULZE ISFORT ET AL: "Helical Complexes Containing Diamide-Bridged Benzene-o-dithiolate/Catecholato Ligands", CHEMISTRY - A EUROPEAN JOURNAL, WILEY - V C H VERLAG GMBH & CO. KGAA, WEINHEIM, DE, vol. 13, no. 8, 5 March 2007 (2007-03-05), pages 2344 - 2357, XP002659522, ISSN: 0947-6539, [retrieved on 20061214], DOI: 10.1002/CHEM.200601167 *
NORIYASU KATO ET AL: "Discovery and pharmacological characterization of-[2-({2-[(2)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 19, no. 23, 23 September 2011 (2011-09-23), pages 7221 - 7227, XP028104550, ISSN: 0968-0896, [retrieved on 20111002], DOI: 10.1016/J.BMC.2011.09.043 *
PITTELKOW ET AL.: "Selective synthesis of carbamate protected polyamines using alkyl phenyl carbonates", SYNTHESIS, vol. 15, 2002, pages 2195 - 2202, XP002736828 *

Also Published As

Publication number Publication date
WO2015104602A2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
EP3402787A4 (en) Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
WO2016071435A3 (en) Synthesis of copanlisib and its dihydrochloride salt
WO2018029711A3 (en) Process for the preparation of venetoclax
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
WO2016108206A3 (en) Processes for preparation of idelalisib and intermediates thereof
EP3694499A4 (en) Novel process for the preparation of lifitegrast
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
EP3717457A4 (en) Process for preparation of enzalutamide using novel intermediate
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2015197534A3 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2015128875A3 (en) A process for preparation of dabigatran etexilate mesylate and intermediates thereof
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
EP3565552A4 (en) An improved process for the preparation of rivaroxaban involving novel intermediate
WO2015104602A3 (en) A process for the preparation of anagliptin and its intermediates thereof
EP3118207A4 (en) Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
WO2017046816A3 (en) Process for the preparation of derivatives of benzodioxole
WO2016079757A3 (en) Novel processes for preparing 5-hydroxymethyl-oxazolidin-2-one derivatives
WO2016007587A3 (en) 3'-substituted-abscisic acid derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14835579

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14835579

Country of ref document: EP

Kind code of ref document: A2